Back to resultsA Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Primary Purpose
Squamous Non-Small Cell Lung Cancer
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Carboplatin
Nab-Paclitaxel
Paclitaxel
Sponsored by
About this trial
This is an interventional treatment trial for Squamous Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
- Previously obtained archival tumor tissue or tissue obtained from biopsy at screening
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end organ function
Exclusion Criteria:
- Active or untreated central nervous system (CNS) metastasis
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Positive test for Human Immunodeficiency Virus (HIV)
- Active hepatitis B or hepatitis C
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
- Severe infection within 4 weeks prior to randomization
- Significant history of cardiovascular disease
Sites / Locations
- Ironwood Cancer & Research Centers
- Highlands Oncology Group
- Southern CA Permanente Med Grp
- Kaiser Permanente Oakland Medical Center
- Kaiser Permanente - Sacramento Medical Center and Medical Offices
- Kaiser Permanente - San Leandro Medical Center
- Kaiser Permanente - Santa Clara
- Kaiser Permanente; Oncology Clinical Trials
- Kaiser Permanente - Walnut Creek
- Rocky Mountain Cancer Center
- Danbury Hospital
- Holy Cross Hospital Inc
- SCRI Florida Cancer Specialists South
- Florida Cancer Specialists
- Hematology Oncology Associates of the Treasure Coast
- Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
- University Cancer & Blood Center, LLC; Research
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
- Central Georgia Cancer Care PC
- Southeastern Regional Medical Center, Inc.
- University of Chicago
- Joliet Oncology-Hematology; Associates, Ltd.
- Quincy Medical Group
- Fort Wayne Med Oncology & Hematology Inc
- Hematology-Oncology; Associates of the Quad Cities
- Siouxland Hematology/Oncology
- Lahey Clinic Med Ctr
- Norton Cancer Institute
- Ochsner Clinic Foundation
- New England Cancer Specialists
- Southcoast Health System; Southcoast Centers For Cancer Care
- St. Joseph Mercy Health System
- Karmanos Cancer Institute
- St. Luke's Regional Cancer Center
- Hematology and Oncology Associates at Bridgepoint
- Billings Clinic
- Valley Hospital; Oncology Research
- Regional Cancer Care Associates LLC
- Clinical Research Alliance
- W.G. Bill Hefner VA Medical Center
- University of Cincinnati
- Mark H. Zangmeister Center
- Oncology Hematology Care, Inc.
- Oregon Health & Science Uni
- St. Luke's Cancer Care Associates
- Maryland Oncology Hematology (Lanham) - USOR
- Allegheny Cancer Center
- Univ of Pittsburgh Medical Ctr
- SCRI Tennessee Oncology Chattanooga
- Tennessee Cancer Specialists
- SCRI The Center For Cancer and Blood Disorders
- Longview Cancer Center
- Virginia Cancer Specialists, PC
- Virginia Oncology Associates
- Blue Ridge Cancer Care
- Providence Regional Cancer Partnership
- Medical Oncology Associates
- Fundación CENIT para la Investigación en Neurociencias
- Sanatorio Allende
- Centro Oncologico Riojano Integral (CORI)
- Clínica Pergamino
- Fundacion Koriza
- Centro de Investigacion; Clinica - Clinica Viedma S.A.
- Chris O'Brien Lifehouse
- Calvary Mater Newcastle; Medical Oncology
- Prince Charles Hospital
- Townsville Hospital
- Princess Alexandra Hospital
- Royal Adelaide Hospital
- Austin Health
- Cabrini Hospital Malvern
- Sunshine Hospital
- Sir Charles Gairdner Hospital
- Paracelsus Medizinische Privatuniversität
- Cliniques Universitaires St-Luc
- CHU Sart-Tilman
- Clinique Ste-Elisabeth
- Werken Glorieux VZW
- GasthuisZusters Antwerpen
- Cenantron - Centro Avancado de Tratamento Oncologico
- Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica
- Liga Norte Riograndense Contra O Câncer
- IPCEM; Instituto de Pesquisa de Estudos Multicêntricos
- Hospital Bruno Born
- Hospital das Clinicas - UFRGS
- Hospital Mae de Deus
- *X*Fundação Pio XII Hospital de Câncer de Barretos
- Hospital de Base de Sao Jose do Rio Preto
- Hospital Do Cancer A C Camargo
- Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
- Multiprofile Hospital for Active Treatment Serdika EOOD
- Royal Victoria Regional Health Centre
- William Osler Health Centre
- Lakeridge Health Center
- Cite de La Sante de Laval; Hemato-Oncologie
- Hôpital du Sacré-Coeur de Montreal
- St. Jerome Medical Research
- Health & Care SPA
- Sociedad de Investigaciones Medicas Ltda (SIM)
- CHU de Grenoble
- Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
- Clinique Clémentville
- Hopital de La Source
- Centre Hospitalier Lyon Sud
- Hopital de Pontchaillou; Service de Pneumologie
- Centre Hospitalier Regional Sud Reunion; Service de Pneumologie
- CH de Saint Quentin
- Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques
- Charite - Universitätsmedizin Berlin
- Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie
- Augusta Kranken-Anstalt gGmbH
- Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
- St. Elisabethen Krankenhaus
- Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
- LungenClinic Großhansdorf GmbH
- Krankenhaus Martha-Maria; Halle-Dolau gGmbH
- Universitätsklinikum Hamburg-Eppendorf
- Asklepios Klinik Harburg
- Lungenklinik Hemer
- Universität Des Saarlandes; Klinik für Innere Medizin V
- Fachklinik für Lungenerkrankungen
- Kliniken der Stadt Koln gGmbH
- Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin
- Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie
- Krankenhaus Barmherzige Bruder Regensburg
- Klinikum der Universität Regensburg
- Stiftung Mathias-Spital Rheine
- Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
- Soroka Medical Center
- Hadassah University Hospital - Ein Kerem
- Meir Medical Center; Oncology
- Rabin Medical Center
- Chaim Sheba Medical Center; Oncology Dept
- Rambam Health Corporation; Oncology Institute
- Tel Aviv Sourasky Medical Ctr; Oncology
- Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
- AORN A Cardarelli
- Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
- Azienda Ospedaliera San Camillo Forlanini
- ASL 3 Genovese; DSM
- Fondazione IRCCS Policlinico San Matteo
- IRCCS Giovanni Paolo II Istituto Oncologico
- Policlinico Vittorio Emanuele
- Ospedale Civile - Livorno
- Azienda Ospedaliero Universitaria Pisana
- Ospedale Silvestrini
- Aichi Cancer Center Hospital; Respiratory Medicine
- Nagoya University Hospital; Respiratory Medicine
- National Cancer Center Hospital East; Thoracic Oncology
- National Hospital Organization Shikoku Cancer Center; Internal Medicine
- National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine
- Kyushu University Hospital; Respiratory
- Kobe City Medical Center General Hospital; Respiratory Medicine
- National Hospital Organization Himeji Medical Center
- Hyogo Cancer Center; Thoracic Oncology
- Ibaraki Prefectural Central Hospital; Division of respiratory
- Kanagawa Cancer Center;Thoracic Oncology
- Kyoto University Hospital, Respiratory Medicine
- Sendai Kousei Hospital; Pulmonary Medicine
- Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease
- Okayama University Hospital; Respiratory and Allergy Medicine
- Osaka International Cancer Institute; Thoracic Oncology
- Osaka City Uni Hospital; Respiratory Medicine
- Kansai Medical university Hospital; Thoracic Oncology
- Osaka Habikino Medical Center
- National Hospital Organization Kinki-Chuo Chest Medical Center
- Saitama Cancer Center; Thoracic Oncology
- Shizuoka Cancer Center; Thoracic Oncology
- National Cancer Center Hospital; Thoracic Medical Oncology
- Tokyo Medical University Hospital; Dept of Surgery
- Riga East Clinical University Hospital Latvian Oncology Centre
- Pauls Stradins Clinical University Hospital
- National Cancer Institute
- Centro Universitario Contra El Cancer
- Cancerología
- VU Medisch Centrum; VU University Medical Center
- Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
- Ziekenhuis Gelderse Vallei
- Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose
- St. Antonius Ziekenhuis; R&D Long
- Centro Medico Monte Carmelo
- Hospital Nacional Guillermo Almenara Irigoyen ESSALUD
- Instituto Regional de Enfermedades Neoplásicas Del Norte
- IPO de Lisboa; Servico de Pneumologia
- Hospital Pulido Valente; Servico de Pneumologia
- Centro Hospitalar do Porto - Hospital de Santo António
- Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
- Hospital de Sao Joao; Servico de Pneumologia
- Moscow City Oncology Hospital #62
- Russian Oncology Research Center n.a. N.N. Blokhin
- Clinical Oncology Dispensary
- City Clinical Oncology Dispensary
- Volgograd Regional Clinical Oncology Dispensary
- National University Hospital
- National Cancer Centre
- Univerzitna nemocnica Bratislava
- Narodny onkologicky ustav
- POKO Poprad s.r.o.
- Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia
- Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
- Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
- Hospital Universitario Son Espases
- Complejo Hospitalario Universitario A Coruña
- Complejo Hospitalario Universitario Insular-Materno Infantil
- Hospital Nuestra Senora de Valme
- Hospital Universitario de Canarias
- Hospital del Mar
- Hospital Univ Vall d'Hebron; Servicio de Oncologia
- Hospital Clinic de Barcelona
- Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
- Hospital Universitario Reina Sofia
- Hospital Lucus Augusti; Servicio de Oncologia
- Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
- Hospital Universitario La Paz
- Hospital Ramon y Cajal; Servicio de Oncologia
- Fundación Jimenez Díaz
- Hospital Clinico San Carlos; Servicio de Oncologia
- Hospital Universitario 12 de Octubre
- HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
- Hospital Clinico Universitario de Valencia
- Hospital General Universitario de Valencia
- Hospital Universitario Miguel Servet
- Changhua Christian Hospital; Hematology-Oncology
- Kaohsiung Medical University Hospital; Department of Urology
- Chi Mei Medical Center Liou Ying Campus
- Chang Gung Memorial Hospital Chiayi
- China Medical University Hospital
- National Taiwan Uni Hospital
- Mackay Memorial Hospital
- Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy
- Uzhgorod Central City Clinical Hospital
- MNPE Zaporizhzhia Regional Antitumor Center ZRC
- Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs
- Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council
- MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy
- Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1
- SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine
- ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department
- Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department
- Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Arm A: Atezolizumab + Paclitaxel + Carboplatin
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Arm C: Nab-Paclitaxel + Carboplatin
Arm Description
The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
Outcomes
Primary Outcome Measures
Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.
Overall Survival (OS) in the ITT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Secondary Outcome Measures
OS in the in the Teff Population
OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.
PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.
PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.
PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.
OS in the TC2/3 or IC2/3 Population
OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.
OS in the TC1/2/3 or IC1/2/3 Population
OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.
Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Proportion of participants with an objective response (CR or PR) in the ITT population.
Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.
Event Free Rate at 1 and 2 Years in the ITT Population
Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.
Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population
TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a >= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a >= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A >= 10-point change in the EORTC scale score is perceived by patients as clinically significant.
Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)
PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.
OS in the ITT Population (Arm A and Arm B)
OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.
Percentage of Participants With Adverse Events
Percentage of participants with at least one adverse event.
Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab
Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.
Plasma Concentrations for Paclitaxel
Plasma concentrations for paclitaxel.
Plasma Concentrations for Nab-Paclitaxel
Plasma concentrations for nab-paclitaxel.
Plasma Concentrations for Carboplatin
Plasma concentrations for carboplatin.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02367794
Brief Title
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Official Title
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
June 11, 2015 (Actual)
Primary Completion Date
October 3, 2018 (Actual)
Study Completion Date
February 17, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Squamous Non-Small Cell Lung Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1021 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm A: Atezolizumab + Paclitaxel + Carboplatin
Arm Type
Experimental
Arm Description
The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
Arm Title
Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
Arm Type
Experimental
Arm Description
The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
Arm Title
Arm C: Nab-Paclitaxel + Carboplatin
Arm Type
Active Comparator
Arm Description
The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
Intervention Type
Drug
Intervention Name(s)
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Other Intervention Name(s)
Tecentriq
Intervention Description
Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
Intervention Type
Drug
Intervention Name(s)
Nab-Paclitaxel
Intervention Description
Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population
Description
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
Overall Survival (OS) in the ITT Population
Description
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Time Frame
Up to approximately 39 months after first participant enrolled
Secondary Outcome Measure Information:
Title
OS in the in the Teff Population
Description
OS is defined as the time between the date of randomization and date of death from any cause in the in the Teff Population.
Time Frame
Up to approximately 39 months after first participant enrolled
Title
PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population
Description
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Teff Population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population
Description
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population
Description
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the TC1/2/3 or IC1/2/3 Population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
OS in the TC2/3 or IC2/3 Population
Description
OS is defined as the time between the date of randomization and date of death from any cause, in the TC2/3 or IC2/3 Population.
Time Frame
Up to approximately 39 months after first participant enrolled
Title
OS in the TC1/2/3 or IC1/2/3 Population
Description
OS is defined as the time between the date of randomization and date of death from any cause in the TC1/2/3 or IC1/2/3 Population.
Time Frame
Up to approximately 39 months after first participant enrolled
Title
Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Description
Proportion of participants with an objective response (CR or PR) in the ITT population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population
Description
Duration of response is defined as the time from the first documented objective response to documented PD or death from any cause, whichever occurred first, in the ITT Population.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
Event Free Rate at 1 and 2 Years in the ITT Population
Description
Event free rate at 1 and 2 years is defined as the proportion of participants alive at 1 and 2 years after randomization estimated using Kaplan-Meier (KM) methodology for the ITT population.
Time Frame
1 and 2 years
Title
Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population
Description
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population. The EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC scales and single-item measures will be linearly transformed so that each score has a range of 0-100. A high score for a functional scale represents a high or healthy level of functioning, and a high score for the global health status and HRQoL represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population
Description
TTD was documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi--item scale. In this instance, symptom deterioration will be determined as a >= 10-point increase above baseline in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi-item scale). Confirmed clinically meaningful symptom deterioration will need to be held for the original symptom; a >= 10-point increase above baseline in a symptom score must be held for at least two consecutive assessments or an initial>=10-point increase above baseline followed by death within 3 weeks from the last assessment. A >= 10-point change in the EORTC scale score is perceived by patients as clinically significant.
Time Frame
Up to approximately 30 months after the first participant enrolled
Title
Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population
Description
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms & are scored at individual symptom level, thus have a dyspnea score, chest pain score, & cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 & maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 & 2, 'Cough' score is mean of question 3 & 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea & cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for chest pain score is considered to be clinically significant. (Note: PD=progression of disease)
Time Frame
Baseline up to approximately 30 months after first participant enrolled
Title
PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B)
Description
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first, in the ITT Population Arm A and Arm B.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
OS in the ITT Population (Arm A and Arm B)
Description
OS is defined as the time between the date of randomization and date of death from any cause in the ITT Population, Arm A and Arm B.
Time Frame
Up to approximately 39 months after first participant enrolled
Title
Percentage of Participants With Adverse Events
Description
Percentage of participants with at least one adverse event.
Time Frame
Up to approximately 68 months after first participant enrolled
Title
Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab
Description
Percentage of participants with Anti-therapeutic Antibody (ATA) response to atezolizumab.
Time Frame
Up to approximately 30 months after first participant enrolled
Title
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Description
Maximum observed serum atezolizumab concentration (Cmax). The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Time Frame
Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Title
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Description
Minimum observed serum atezolizumab concentration (Cmin). The predose samples will be collected on the same day of treatment administration.
Time Frame
Predose on Day 1 of Cycles 1-4, 8, 16, every 8 cycle thereafter (up to 30 months), at treatment discontinuation (up to 30 months), and at 120 days after the last dose of atezolizumab (up to approximately 30 months, each cycle is 21 days)
Title
Plasma Concentrations for Paclitaxel
Description
Plasma concentrations for paclitaxel.
Time Frame
Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 180 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Title
Plasma Concentrations for Nab-Paclitaxel
Description
Plasma concentrations for nab-paclitaxel.
Time Frame
Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
Title
Plasma Concentrations for Carboplatin
Description
Plasma concentrations for carboplatin.
Time Frame
Prior to infusion (within same day of treatment administration), 5-10 minutes before the end of infusion, and 1 hour after the end of infusion (infusion duration 15 to 30 minutes) on Day 1 of Cycles 1 and 3 (each cycle is 21 days)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
Previously obtained archival tumor tissue or tissue obtained from biopsy at screening
Measurable disease as defined by RECIST v1.1
Adequate hematologic and end organ function
Exclusion Criteria:
Active or untreated central nervous system (CNS) metastasis
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Pregnant or lactating women
History of autoimmune disease
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan, History of radiation pneumonitis in the radiation field (fibrosis) is permitted
Positive test for Human Immunodeficiency Virus (HIV)
Active hepatitis B or hepatitis C
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
Severe infection within 4 weeks prior to randomization
Significant history of cardiovascular disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Ironwood Cancer & Research Centers
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
Highlands Oncology Group
City
Springdale
State/Province
Arkansas
ZIP/Postal Code
72762
Country
United States
Facility Name
Southern CA Permanente Med Grp
City
Bellflower
State/Province
California
Country
United States
Facility Name
Kaiser Permanente Oakland Medical Center
City
Oakland
State/Province
California
ZIP/Postal Code
94611
Country
United States
Facility Name
Kaiser Permanente - Sacramento Medical Center and Medical Offices
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Kaiser Permanente - San Leandro Medical Center
City
San Leandro
State/Province
California
ZIP/Postal Code
94577
Country
United States
Facility Name
Kaiser Permanente - Santa Clara
City
Santa Clara
State/Province
California
ZIP/Postal Code
95051
Country
United States
Facility Name
Kaiser Permanente; Oncology Clinical Trials
City
Vallejo
State/Province
California
ZIP/Postal Code
94589
Country
United States
Facility Name
Kaiser Permanente - Walnut Creek
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94596
Country
United States
Facility Name
Rocky Mountain Cancer Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Danbury Hospital
City
Danbury
State/Province
Connecticut
ZIP/Postal Code
06810
Country
United States
Facility Name
Holy Cross Hospital Inc
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Facility Name
SCRI Florida Cancer Specialists South
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33916
Country
United States
Facility Name
Florida Cancer Specialists
City
Palm Beach Gardens
State/Province
Florida
ZIP/Postal Code
33410
Country
United States
Facility Name
Hematology Oncology Associates of the Treasure Coast
City
Port Saint Lucie
State/Province
Florida
ZIP/Postal Code
34952
Country
United States
Facility Name
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
University Cancer & Blood Center, LLC; Research
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Facility Name
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
City
Carrollton
State/Province
Georgia
ZIP/Postal Code
30117
Country
United States
Facility Name
Central Georgia Cancer Care PC
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Facility Name
Southeastern Regional Medical Center, Inc.
City
Newnan
State/Province
Georgia
ZIP/Postal Code
30265
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Joliet Oncology-Hematology; Associates, Ltd.
City
Joliet
State/Province
Illinois
ZIP/Postal Code
60435
Country
United States
Facility Name
Quincy Medical Group
City
Quincy
State/Province
Illinois
ZIP/Postal Code
62301
Country
United States
Facility Name
Fort Wayne Med Oncology & Hematology Inc
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46845
Country
United States
Facility Name
Hematology-Oncology; Associates of the Quad Cities
City
Bettendorf
State/Province
Iowa
ZIP/Postal Code
52722
Country
United States
Facility Name
Siouxland Hematology/Oncology
City
Sioux City
State/Province
Iowa
ZIP/Postal Code
51101
Country
United States
Facility Name
Lahey Clinic Med Ctr
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
02421
Country
United States
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
New England Cancer Specialists
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Facility Name
Southcoast Health System; Southcoast Centers For Cancer Care
City
Fairhaven
State/Province
Massachusetts
ZIP/Postal Code
02719
Country
United States
Facility Name
St. Joseph Mercy Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
St. Luke's Regional Cancer Center
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55805
Country
United States
Facility Name
Hematology and Oncology Associates at Bridgepoint
City
Tupelo
State/Province
Mississippi
ZIP/Postal Code
38801
Country
United States
Facility Name
Billings Clinic
City
Billings
State/Province
Montana
ZIP/Postal Code
59102
Country
United States
Facility Name
Valley Hospital; Oncology Research
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States
Facility Name
Regional Cancer Care Associates LLC
City
Sewell
State/Province
New Jersey
ZIP/Postal Code
08080
Country
United States
Facility Name
Clinical Research Alliance
City
Westbury
State/Province
New York
ZIP/Postal Code
11590
Country
United States
Facility Name
W.G. Bill Hefner VA Medical Center
City
Salisbury
State/Province
North Carolina
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45203-0542
Country
United States
Facility Name
Mark H. Zangmeister Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43219
Country
United States
Facility Name
Oncology Hematology Care, Inc.
City
Hamilton
State/Province
Ohio
ZIP/Postal Code
45103
Country
United States
Facility Name
Oregon Health & Science Uni
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
St. Luke's Cancer Care Associates
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Facility Name
Maryland Oncology Hematology (Lanham) - USOR
City
Gettysburg
State/Province
Pennsylvania
ZIP/Postal Code
17325
Country
United States
Facility Name
Allegheny Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
Univ of Pittsburgh Medical Ctr
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
SCRI Tennessee Oncology Chattanooga
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
Tennessee Cancer Specialists
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
SCRI The Center For Cancer and Blood Disorders
City
Denton
State/Province
Texas
ZIP/Postal Code
76210
Country
United States
Facility Name
Longview Cancer Center
City
Longview
State/Province
Texas
ZIP/Postal Code
75601
Country
United States
Facility Name
Virginia Cancer Specialists, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Virginia Oncology Associates
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Facility Name
Blue Ridge Cancer Care
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
Facility Name
Providence Regional Cancer Partnership
City
Everett
State/Province
Washington
ZIP/Postal Code
98201
Country
United States
Facility Name
Medical Oncology Associates
City
Spokane
State/Province
Washington
ZIP/Postal Code
99208
Country
United States
Facility Name
Fundación CENIT para la Investigación en Neurociencias
City
Buenos Aires
ZIP/Postal Code
C1125ABD
Country
Argentina
Facility Name
Sanatorio Allende
City
Cordoba
ZIP/Postal Code
X5000JHQ
Country
Argentina
Facility Name
Centro Oncologico Riojano Integral (CORI)
City
La Rioja
ZIP/Postal Code
F5300COE
Country
Argentina
Facility Name
Clínica Pergamino
City
Pergamino
ZIP/Postal Code
B2700CPM
Country
Argentina
Facility Name
Fundacion Koriza
City
Santa Rosa
ZIP/Postal Code
L6304BOC
Country
Argentina
Facility Name
Centro de Investigacion; Clinica - Clinica Viedma S.A.
City
Viedma
ZIP/Postal Code
R8500ACE
Country
Argentina
Facility Name
Chris O'Brien Lifehouse
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
Calvary Mater Newcastle; Medical Oncology
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Prince Charles Hospital
City
Chermside
State/Province
Queensland
ZIP/Postal Code
4032
Country
Australia
Facility Name
Townsville Hospital
City
Townsville
State/Province
Queensland
ZIP/Postal Code
4810
Country
Australia
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Austin Health
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Cabrini Hospital Malvern
City
Malvern
State/Province
Victoria
ZIP/Postal Code
3144
Country
Australia
Facility Name
Sunshine Hospital
City
St Albans
State/Province
Victoria
ZIP/Postal Code
3021
Country
Australia
Facility Name
Sir Charles Gairdner Hospital
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Paracelsus Medizinische Privatuniversität
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Cliniques Universitaires St-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
CHU Sart-Tilman
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Clinique Ste-Elisabeth
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Facility Name
Werken Glorieux VZW
City
Ronse
ZIP/Postal Code
9600
Country
Belgium
Facility Name
GasthuisZusters Antwerpen
City
Wilrijk
ZIP/Postal Code
2610
Country
Belgium
Facility Name
Cenantron - Centro Avancado de Tratamento Oncologico
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
30130-090
Country
Brazil
Facility Name
Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica
City
Londrina
State/Province
PR
ZIP/Postal Code
86 015 520
Country
Brazil
Facility Name
Liga Norte Riograndense Contra O Câncer
City
Natal
State/Province
RN
ZIP/Postal Code
59040150
Country
Brazil
Facility Name
IPCEM; Instituto de Pesquisa de Estudos Multicêntricos
City
Caxias do Sul
State/Province
RS
ZIP/Postal Code
95070-560
Country
Brazil
Facility Name
Hospital Bruno Born
City
Lajeado
State/Province
RS
ZIP/Postal Code
95900-000
Country
Brazil
Facility Name
Hospital das Clinicas - UFRGS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-903
Country
Brazil
Facility Name
Hospital Mae de Deus
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90470-340
Country
Brazil
Facility Name
*X*Fundação Pio XII Hospital de Câncer de Barretos
City
Barretos
State/Province
SP
ZIP/Postal Code
14784-400
Country
Brazil
Facility Name
Hospital de Base de Sao Jose do Rio Preto
City
Sao Jose do Rio Preto
State/Province
SP
ZIP/Postal Code
15090-000
Country
Brazil
Facility Name
Hospital Do Cancer A C Camargo
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01525-001
Country
Brazil
Facility Name
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria
Facility Name
Multiprofile Hospital for Active Treatment Serdika EOOD
City
Sofia
ZIP/Postal Code
1303
Country
Bulgaria
Facility Name
Royal Victoria Regional Health Centre
City
Barrie
State/Province
Ontario
ZIP/Postal Code
L4M 6M2
Country
Canada
Facility Name
William Osler Health Centre
City
Etobicoke
State/Province
Ontario
ZIP/Postal Code
M9V 1R8
Country
Canada
Facility Name
Lakeridge Health Center
City
Oshawa
State/Province
Ontario
ZIP/Postal Code
L1J 2J2
Country
Canada
Facility Name
Cite de La Sante de Laval; Hemato-Oncologie
City
Laval
State/Province
Quebec
ZIP/Postal Code
H7M 3L9
Country
Canada
Facility Name
Hôpital du Sacré-Coeur de Montreal
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4J 1C5
Country
Canada
Facility Name
St. Jerome Medical Research
City
St. Jerome
State/Province
Quebec
ZIP/Postal Code
J7Z 5T3
Country
Canada
Facility Name
Health & Care SPA
City
Santiago
ZIP/Postal Code
7500006
Country
Chile
Facility Name
Sociedad de Investigaciones Medicas Ltda (SIM)
City
Temuco
ZIP/Postal Code
4810469
Country
Chile
Facility Name
CHU de Grenoble
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
Ctr Jean Bernard Clin V. Hugo; Service d'Oncologie Méd
City
Le Mans
ZIP/Postal Code
72000
Country
France
Facility Name
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
City
Lyon
ZIP/Postal Code
69008
Country
France
Facility Name
Clinique Clémentville
City
Montpellier
ZIP/Postal Code
34070
Country
France
Facility Name
Hopital de La Source
City
Orleans
ZIP/Postal Code
45067
Country
France
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
Hopital de Pontchaillou; Service de Pneumologie
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Centre Hospitalier Regional Sud Reunion; Service de Pneumologie
City
Saint Pierre
ZIP/Postal Code
97448
Country
France
Facility Name
CH de Saint Quentin
City
Saint Quentin
ZIP/Postal Code
2100
Country
France
Facility Name
Hôpital d'Instruction des Armées de Sainte Anne; Service Pharmacie Essais Cliniques
City
Toulon Cedex 9
ZIP/Postal Code
83800
Country
France
Facility Name
Charite - Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Facility Name
Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie
City
Bielefeld
ZIP/Postal Code
33611
Country
Germany
Facility Name
Augusta Kranken-Anstalt gGmbH
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
St. Elisabethen Krankenhaus
City
Frankfurt am Main
ZIP/Postal Code
60487
Country
Germany
Facility Name
Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
City
Gerlingen
ZIP/Postal Code
70839
Country
Germany
Facility Name
LungenClinic Großhansdorf GmbH
City
Großhansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Krankenhaus Martha-Maria; Halle-Dolau gGmbH
City
Halle
ZIP/Postal Code
06120
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Asklepios Klinik Harburg
City
Hamburg
ZIP/Postal Code
21075
Country
Germany
Facility Name
Lungenklinik Hemer
City
Hemer
ZIP/Postal Code
58675
Country
Germany
Facility Name
Universität Des Saarlandes; Klinik für Innere Medizin V
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Facility Name
Fachklinik für Lungenerkrankungen
City
Immenhausen
ZIP/Postal Code
34376
Country
Germany
Facility Name
Kliniken der Stadt Koln gGmbH
City
Koln
ZIP/Postal Code
51109
Country
Germany
Facility Name
Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin
City
Minden
ZIP/Postal Code
32429
Country
Germany
Facility Name
Klinikum Bogenhausen; Klinik für Pneumologie und Pneumologische Onkologie
City
München
ZIP/Postal Code
81925
Country
Germany
Facility Name
Krankenhaus Barmherzige Bruder Regensburg
City
Regensburg
ZIP/Postal Code
93049
Country
Germany
Facility Name
Klinikum der Universität Regensburg
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Stiftung Mathias-Spital Rheine
City
Rheine
ZIP/Postal Code
48431
Country
Germany
Facility Name
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
City
Villingen-Schwenningen
ZIP/Postal Code
78052
Country
Germany
Facility Name
Soroka Medical Center
City
Beer Sheva
ZIP/Postal Code
8410101
Country
Israel
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Facility Name
Meir Medical Center; Oncology
City
Kfar-Saba
ZIP/Postal Code
4428164
Country
Israel
Facility Name
Rabin Medical Center
City
Petach Tiqwa
ZIP/Postal Code
4941492
Country
Israel
Facility Name
Chaim Sheba Medical Center; Oncology Dept
City
Ramat Gan
ZIP/Postal Code
5262100
Country
Israel
Facility Name
Rambam Health Corporation; Oncology Institute
City
Rambam
ZIP/Postal Code
3525408
Country
Israel
Facility Name
Tel Aviv Sourasky Medical Ctr; Oncology
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Facility Name
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
City
Avellino
State/Province
Campania
ZIP/Postal Code
83100
Country
Italy
Facility Name
AORN A Cardarelli
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Seconda Università degli Studi di Napoli; Farmacia Centralizzata
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
Azienda Ospedaliera San Camillo Forlanini
City
Roma
State/Province
Lazio
ZIP/Postal Code
00152
Country
Italy
Facility Name
ASL 3 Genovese; DSM
City
Genova
State/Province
Liguria
ZIP/Postal Code
16147
Country
Italy
Facility Name
Fondazione IRCCS Policlinico San Matteo
City
Pavia
State/Province
Lombardia
ZIP/Postal Code
27100
Country
Italy
Facility Name
IRCCS Giovanni Paolo II Istituto Oncologico
City
Bari
State/Province
Puglia
ZIP/Postal Code
70124
Country
Italy
Facility Name
Policlinico Vittorio Emanuele
City
Catania
State/Province
Sicilia
ZIP/Postal Code
95123
Country
Italy
Facility Name
Ospedale Civile - Livorno
City
Livorno
State/Province
Toscana
ZIP/Postal Code
57124
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Pisana
City
Pisa
State/Province
Toscana
ZIP/Postal Code
56100
Country
Italy
Facility Name
Ospedale Silvestrini
City
Perugia
State/Province
Umbria
ZIP/Postal Code
06122
Country
Italy
Facility Name
Aichi Cancer Center Hospital; Respiratory Medicine
City
Aichi
ZIP/Postal Code
464-8681
Country
Japan
Facility Name
Nagoya University Hospital; Respiratory Medicine
City
Aichi
ZIP/Postal Code
466-8560
Country
Japan
Facility Name
National Cancer Center Hospital East; Thoracic Oncology
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Facility Name
National Hospital Organization Shikoku Cancer Center; Internal Medicine
City
Ehime
ZIP/Postal Code
791-0280
Country
Japan
Facility Name
National Hospital Organization Kyushu Medical Center; Respiratory Internal Medicine
City
Fukuoka
ZIP/Postal Code
810-8563
Country
Japan
Facility Name
Kyushu University Hospital; Respiratory
City
Fukuoka
ZIP/Postal Code
812-8582
Country
Japan
Facility Name
Kobe City Medical Center General Hospital; Respiratory Medicine
City
Hyogo
ZIP/Postal Code
650-0047
Country
Japan
Facility Name
National Hospital Organization Himeji Medical Center
City
Hyogo
ZIP/Postal Code
670-8520
Country
Japan
Facility Name
Hyogo Cancer Center; Thoracic Oncology
City
Hyogo
ZIP/Postal Code
673-8558
Country
Japan
Facility Name
Ibaraki Prefectural Central Hospital; Division of respiratory
City
Ibaraki
ZIP/Postal Code
309-1793
Country
Japan
Facility Name
Kanagawa Cancer Center;Thoracic Oncology
City
Kanagawa
ZIP/Postal Code
241-8515
Country
Japan
Facility Name
Kyoto University Hospital, Respiratory Medicine
City
Kyoto
ZIP/Postal Code
606-8507
Country
Japan
Facility Name
Sendai Kousei Hospital; Pulmonary Medicine
City
Miyagi
ZIP/Postal Code
980-0873
Country
Japan
Facility Name
Niigata University Medical & Dental Hospital; Respiratory Medicine and Infectious Disease
City
Niigata
ZIP/Postal Code
951-8520
Country
Japan
Facility Name
Okayama University Hospital; Respiratory and Allergy Medicine
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Facility Name
Osaka International Cancer Institute; Thoracic Oncology
City
Osaka
ZIP/Postal Code
541-8567
Country
Japan
Facility Name
Osaka City Uni Hospital; Respiratory Medicine
City
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Kansai Medical university Hospital; Thoracic Oncology
City
Osaka
ZIP/Postal Code
573-1191
Country
Japan
Facility Name
Osaka Habikino Medical Center
City
Osaka
ZIP/Postal Code
583-8588
Country
Japan
Facility Name
National Hospital Organization Kinki-Chuo Chest Medical Center
City
Sakai-shi
ZIP/Postal Code
591-8555
Country
Japan
Facility Name
Saitama Cancer Center; Thoracic Oncology
City
Satima
ZIP/Postal Code
362-0806
Country
Japan
Facility Name
Shizuoka Cancer Center; Thoracic Oncology
City
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
Facility Name
National Cancer Center Hospital; Thoracic Medical Oncology
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Facility Name
Tokyo Medical University Hospital; Dept of Surgery
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
Riga East Clinical University Hospital Latvian Oncology Centre
City
Riga
ZIP/Postal Code
LV-1079
Country
Latvia
Facility Name
Pauls Stradins Clinical University Hospital
City
Rīga
ZIP/Postal Code
LV-1002
Country
Latvia
Facility Name
National Cancer Institute
City
Vilnius
ZIP/Postal Code
08660
Country
Lithuania
Facility Name
Centro Universitario Contra El Cancer
City
Monterrey
ZIP/Postal Code
64020
Country
Mexico
Facility Name
Cancerología
City
Queretaro
ZIP/Postal Code
76090
Country
Mexico
Facility Name
VU Medisch Centrum; VU University Medical Center
City
Amsterdam
ZIP/Postal Code
1007 MB
Country
Netherlands
Facility Name
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
City
Amsterdam
ZIP/Postal Code
1066 CX
Country
Netherlands
Facility Name
Ziekenhuis Gelderse Vallei
City
EDE
ZIP/Postal Code
6716 RP
Country
Netherlands
Facility Name
Catharina Hospital; Afdeling Longgeneeskunde en Tuberculose
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
St. Antonius Ziekenhuis; R&D Long
City
Nieuwegein
ZIP/Postal Code
3435 CM
Country
Netherlands
Facility Name
Centro Medico Monte Carmelo
City
Arequipa
ZIP/Postal Code
04001
Country
Peru
Facility Name
Hospital Nacional Guillermo Almenara Irigoyen ESSALUD
City
Lima
ZIP/Postal Code
Lima 13
Country
Peru
Facility Name
Instituto Regional de Enfermedades Neoplásicas Del Norte
City
Trujillo
ZIP/Postal Code
12345
Country
Peru
Facility Name
IPO de Lisboa; Servico de Pneumologia
City
Lisboa
ZIP/Postal Code
1099-023
Country
Portugal
Facility Name
Hospital Pulido Valente; Servico de Pneumologia
City
Lisboa
ZIP/Postal Code
1796-001
Country
Portugal
Facility Name
Centro Hospitalar do Porto - Hospital de Santo António
City
Porto
ZIP/Postal Code
4099-001
Country
Portugal
Facility Name
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Hospital de Sao Joao; Servico de Pneumologia
City
Porto
ZIP/Postal Code
4200
Country
Portugal
Facility Name
Moscow City Oncology Hospital #62
City
Moscovskaya Oblast
State/Province
Moskovskaja Oblast
ZIP/Postal Code
143423
Country
Russian Federation
Facility Name
Russian Oncology Research Center n.a. N.N. Blokhin
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
Clinical Oncology Dispensary
City
Omsk
ZIP/Postal Code
644013
Country
Russian Federation
Facility Name
City Clinical Oncology Dispensary
City
Saint-Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Volgograd Regional Clinical Oncology Dispensary
City
Volgograd
ZIP/Postal Code
400138
Country
Russian Federation
Facility Name
National University Hospital
City
Singapore
ZIP/Postal Code
119074
Country
Singapore
Facility Name
National Cancer Centre
City
Singapore
ZIP/Postal Code
169610
Country
Singapore
Facility Name
Univerzitna nemocnica Bratislava
City
Bratislava
ZIP/Postal Code
813 69
Country
Slovakia
Facility Name
Narodny onkologicky ustav
City
Bratislava
ZIP/Postal Code
833 10
Country
Slovakia
Facility Name
POKO Poprad s.r.o.
City
Poprad
ZIP/Postal Code
058 01
Country
Slovakia
Facility Name
Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia
City
L'Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
8208
Country
Spain
Facility Name
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
City
Santander
State/Province
Cantabria
ZIP/Postal Code
39008
Country
Spain
Facility Name
Hospital Universitario Son Espases
City
Palma De Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07014
Country
Spain
Facility Name
Complejo Hospitalario Universitario A Coruña
City
A Coruña
State/Province
LA Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Complejo Hospitalario Universitario Insular-Materno Infantil
City
Las Palmas de Gran Canaria
State/Province
LAS Palmas
ZIP/Postal Code
35016
Country
Spain
Facility Name
Hospital Nuestra Senora de Valme
City
Seville
State/Province
Sevilla
ZIP/Postal Code
41014
Country
Spain
Facility Name
Hospital Universitario de Canarias
City
S. Cristobal De La Laguna
State/Province
Tenerife
ZIP/Postal Code
38320
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Univ Vall d'Hebron; Servicio de Oncologia
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Hospital Universitario Reina Sofia
City
Cordoba
ZIP/Postal Code
14008
Country
Spain
Facility Name
Hospital Lucus Augusti; Servicio de Oncologia
City
Lugo
ZIP/Postal Code
27003
Country
Spain
Facility Name
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
280146
Country
Spain
Facility Name
Hospital Ramon y Cajal; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Fundación Jimenez Díaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Clinico San Carlos; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Hospital General Universitario de Valencia
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Hospital Universitario Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Changhua Christian Hospital; Hematology-Oncology
City
Changhua
ZIP/Postal Code
500
Country
Taiwan
Facility Name
Kaohsiung Medical University Hospital; Department of Urology
City
Kaohsiung City
ZIP/Postal Code
807
Country
Taiwan
Facility Name
Chi Mei Medical Center Liou Ying Campus
City
Liuying Township
ZIP/Postal Code
736
Country
Taiwan
Facility Name
Chang Gung Memorial Hospital Chiayi
City
Putzu
ZIP/Postal Code
613
Country
Taiwan
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
National Taiwan Uni Hospital
City
Taipei City
ZIP/Postal Code
10041
Country
Taiwan
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
104
Country
Taiwan
Facility Name
Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy
City
Dnipropetrovsk
State/Province
Katerynoslav Governorate
ZIP/Postal Code
49102
Country
Ukraine
Facility Name
Uzhgorod Central City Clinical Hospital
City
Uzhhorod
State/Province
Katerynoslav Governorate
ZIP/Postal Code
88000
Country
Ukraine
Facility Name
MNPE Zaporizhzhia Regional Antitumor Center ZRC
City
Zaporizhzhia
State/Province
Katerynoslav Governorate
ZIP/Postal Code
69040
Country
Ukraine
Facility Name
Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs
City
Kharkiv
State/Province
Kharkiv Governorate
ZIP/Postal Code
61070
Country
Ukraine
Facility Name
Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council
City
Vinnytsia
State/Province
KIEV Governorate
ZIP/Postal Code
21029
Country
Ukraine
Facility Name
MI of the Lviv Regional Council Lviv Oncology Regional Treatment and Diagnostic Centre; Chemotherapy
City
Lviv
State/Province
Volhynian Governorate
ZIP/Postal Code
79031
Country
Ukraine
Facility Name
Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary; Surgery Department #1
City
Chernivtsi
ZIP/Postal Code
58013
Country
Ukraine
Facility Name
SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine
City
Kharkiv
ZIP/Postal Code
61024
Country
Ukraine
Facility Name
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department
City
Kryvyi Rih
ZIP/Postal Code
50048
Country
Ukraine
Facility Name
Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department
City
Poltava
ZIP/Postal Code
36011
Country
Ukraine
Facility Name
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
City
Sumy
ZIP/Postal Code
40005
Country
Ukraine
12. IPD Sharing Statement
Citations:
PubMed Identifier
35511917
Citation
Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.
Results Reference
derived
Learn more about this trial
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
We'll reach out to this number within 24 hrs